Alphatec Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ATEC in the last 7 days.
Alphatec (ATEC) shares rose 19.7% to $10.58 on strong Q2 2026 results, with EPS of $0.07 and revenue of $213.5M. The company expects full-year revenue of $882M. Analysts forecast Q3 EPS of $0.11 and revenue of $224.28M. ClearPoint Neuro (CLPT) also mentioned, up 1.8% to $13.72.
Alphatec Holdings (ATEC) surged 19.67% after its CEO bought $1 million in stock. The medtech company focuses on spinal surgery tech and has strong growth metrics, with Wall Street analysts averaging a $17 price target. Other stocks mentioned include HPE, NTA, INSP, CVI, and INTC, with notable gains in September.
Alphatec Holdings (ATEC) stock rose 19.1% after CEO Patrick Miles bought 115,000 shares for $1.01M at $8.81 each. The company reported Q2 revenue of $213.5M, up 15% YoY, and reaffirmed FY2026 guidance of $882M. The move coincided with a broader market rebound, with the S&P 500 and Nasdaq gaining 1.0% and 1.1% respectively.
Recent ATEC coverage spans earnings, financial news and insider activity.
In the last 30 days, ATEC insiders filed 1 SEC Form 4 transaction — 1 purchase ($1.0M) and no sales. The most active reporter was Miles Patrick, CEO, with 1 filing.
The earnings beat and strong revenue drive a sharp price rally, suggesting further upside if guidance holds.
The headline catalyst is a same-day insider buy tied to improving operating momentum, which can support near-term sentiment and momentum trading.
Insider purchase signals confidence and may fuel a short‑squeeze, supporting further upside.
Significant insider purchase suggests confidence in Alphatec's prospects, potentially supporting short-term price upside.
ATEC’s earnings call provides fresh, decision-relevant guidance updates and operating KPIs (cases, surgeons, biologics attachment) that can drive near-term estimate revisions.
AlphAI scores every news story that mentions ATEC with an AI model for sentiment and relevance, and aggregates insider trades from Alphatec Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alphatec (ATEC) shares rose 19.7% to $10.58 on strong Q2 2026 results, with EPS of $0.07 and revenue of $213.5M. The company expects full-year revenue of $882M. Analysts forecast Q3 EPS of $0.11 and revenue of $224.28M. ClearPoint Neuro (CLPT) also mentioned, up 1.8% to $13.72.
2 min readAlphatec Holdings (ATEC) surged 19.67% after its CEO bought $1 million in stock. The medtech company focuses on spinal surgery tech and has strong growth metrics, with Wall Street analysts averaging a $17 price target. Other stocks mentioned include HPE, NTA, INSP, CVI, and INTC, with notable gains in September.
6 min readAlphatec Holdings (ATEC) stock rose 19.1% after CEO Patrick Miles bought 115,000 shares for $1.01M at $8.81 each. The company reported Q2 revenue of $213.5M, up 15% YoY, and reaffirmed FY2026 guidance of $882M. The move coincided with a broader market rebound, with the S&P 500 and Nasdaq gaining 1.0% and 1.1% respectively.
2 min readMiles Patrick (CEO) purchased 115,000 shares of Alphatec Holdings, Inc. (ATEC) at $8.81 ($1.01M total) on 2026-09-10.
1 min readAlphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose to $36 million, up 53%, with GAAP gross margin 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
6 min readAlphatec Holdings (ATEC) reported Q2 results with a reduced net loss of $25.78 million year over year and reaffirmed 2026 revenue guidance of about $882 million, according to the company. It also filed an $8.12 million shelf registration for 800,000 common shares tied to an ESOP. The update supported a 5.9% stock rise.
4 min readAlphatec Holdings (ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose 53% to $36 million, and GAAP gross margin was 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
7 min readAlphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.
6 min readAlphatec Holdings (Nasdaq: ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year. Surgical revenue was $196 million, up 17%, driven by 20% case volume growth. Adjusted EBITDA was $36 million, 17% of revenue. The company reaffirmed its 2026 outlook: revenue about $882 million and adjusted EBITDA about $140 million.
4 min readAlphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSBAD, Calif., August 4, 2026 – Alphatec Hold
6 min read
